Senseonics Holdings Reports Strong Q2 Revenue Growth, with 37% YoY Increase to $6.6M

Senseonics Holdings reported Q2 revenue growth of 37% YoY, totaling $6.6 million, driven by a 79% increase in new patient starts in the US. The company maintains its full-year 2025 revenue guidance of $34-38 million, anticipating a doubling of its global patient base and improved gross margins.

Senseonics Holdings, Inc. (NYSE American: SENS) reported its second-quarter financial results, highlighting significant revenue growth and strategic advancements. The company generated $6.6 million in revenue for the period ended June 30, 2025, representing a 37% year-over-year (YoY) increase. This growth was primarily driven by a 79% increase in new patient starts in the U.S. [1].

The company's Eversense 365 product, a long-term, implantable continuous glucose monitoring (CGM) system, continues to drive the growth. The second quarter saw a notable expansion of direct-to-consumer (DTC) advertising campaigns, which resulted in a 50% increase in leads over the prior three-month average. Additionally, the company completed the transition of providers to Eon Care from the Nurse Practitioner Group (NPG), now supporting 38 providers to enhance patient access to insertions [1].

Senseonics also reported a gross profit of $3.1 million, up from $0.3 million in the prior year. This increase was attributed to improved margins on the 365-day product and a one-time gain from recovered value-added tax. Research and development expenses decreased by $3.1 million YoY, primarily due to reduced clinical studies spend and consultant costs. Selling, general, and administrative expenses increased by $0.7 million to $9.7 million, driven by higher sales commissions and personnel costs to support the Eon Care inserter network [1].

The company's net loss for the second quarter was $14.5 million, a decrease of $5.8 million from the prior year. This improvement was primarily due to enhanced gross profit margins on Eversense 365 sales in the U.S. and reduced research and development costs [1].

Senseonics maintains its full-year 2025 revenue guidance of $34-38 million, anticipating a doubling of its global patient base. The company expects approximately one-third of revenue to be generated in the first half of 2025, with the remaining two-thirds generated in the second half, weighted towards the fourth quarter due to the once-a-year reorder dynamics of Eversense 365 following its Q4 launch [1].

In addition to these financial results, Senseonics entered into a commercial development agreement with Sequel Med Tech to integrate the twiist™ automated insulin delivery (AID) system with Eversense 365, with a launch expected in the fourth quarter of 2025. The company also raised $77.8 million in total gross proceeds, including $57.5 million from a public offering and $20.3 million from Abbott in a concurrent private placement, to fund the ongoing launch of Eversense 365 and continued development of pipeline products [1].

Senseonics' strategic initiatives and strong financial performance position the company for increased shareholder value and continued growth in the global diabetes management market.

References:
[1] https://www.senseonics.com/investor-relations/news-releases/2025/08-06-2025-210524066